<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36551891</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case-Control Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines10123135</ELocationID><Abstract><AbstractText>Long COVID is a complex condition affecting quality of life, with limited therapeutic options. We investigated the occurrence of long COVID in subjects receiving early therapy with monoclonal antibodies (mAbs) or antivirals to reduce the risk of COVID-19 progression. In this retrospective study we enrolled 737 adult patients (aged 65.16 &#xb1; 13.46; 361F), who experienced COVID-19 between January 2021 and March 2022. Antiviral or mAbs were administered to symptomatic patients who did not require oxygen therapy or hospital admission for SARS-CoV-2 infection, and who were at high risk of progression to severe disease, as identified by age &gt; 65 years or the presence of comorbidities. Long COVID, defined as newly or persistent long-term symptoms 4&#x2009;weeks after the onset of the acute illness, was reported in 204 cases (28%). Age (OR 1.03; p &lt; 0.001), gender (OR 1.88; p &lt; 0.001) and at least three comorbidities (OR 3.49; p = 0.049) were directly associated with long COVID; conversely, vaccination (OR 0.59; p = 0.005) and mAbs/antivirals (OR 0.44; p = 0.002) were independently associated with a reduced risk of long COVID. At a propensity-score-matched analysis, the mAbs/antivirals group had a significantly lower occurrence of long COVID in comparison with untreated controls (11% vs. 34%; p = 0.001). In conclusion, mAbs and antivirals administered against the progression of COVID-19 were associated with a reduced risk of long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cimellaro</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5223-4402</Identifier><AffiliationInfo><Affiliation>Internal Medicine Unit, Department of Medicine, "Pugliese-Ciaccio" Hospital of Catanzaro, Via Pio X n.83, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Addesi</LastName><ForeName>Desir&#xe9;e</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit, Department of Medicine, "Pugliese-Ciaccio" Hospital of Catanzaro, Via Pio X n.83, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavallo</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit, Department of Medicine, "Pugliese-Ciaccio" Hospital of Catanzaro, Via Pio X n.83, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spagnolo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit, Department of Medicine, "Pugliese-Ciaccio" Hospital of Catanzaro, Via Pio X n.83, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suraci</LastName><ForeName>Edoardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit, Department of Medicine, "Pugliese-Ciaccio" Hospital of Catanzaro, Via Pio X n.83, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordaro</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit, Department of Medicine, "Pugliese-Ciaccio" Hospital of Catanzaro, Via Pio X n.83, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit, Department of Medicine, "Pugliese-Ciaccio" Hospital of Catanzaro, Via Pio X n.83, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passafaro</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Coordination of Special Unit of Continuity Care for Local Health Authority, Via Vinicio Cortese n.25, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colosimo</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology and Virology Unit, Service Department, "Pugliese-Ciaccio" Hospital of Catanzaro, Via Pio X n.83, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pintaudi</LastName><ForeName>Medea</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurophysiology and Neurobiology Unit, Department of Medicine, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo n.200, 00128 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pintaudi</LastName><ForeName>Carmelo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit, Department of Medicine, "Pugliese-Ciaccio" Hospital of Catanzaro, Via Pio X n.83, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>On Behalf Of The CATAnzaro LOng Covid Cataloco Study Group</LastName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36551891</ArticleId><ArticleId IdType="pmc">PMC9775930</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10123135</ArticleId><ArticleId IdType="pii">biomedicines10123135</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gandhi R.T., Lynch J.B., Del Rio C. Mild or Moderate COVID-19. N. Engl. J. Med. 2020;383:1757&#x2013;1766. doi: 10.1056/NEJMcp2009249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2009249</ArticleId><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin D.A., Gulick R.M., Martinez F.J. Severe COVID-19. N. Engl. J. Med. 2020;383:2451&#x2013;2460. doi: 10.1056/NEJMcp2009575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2009575</ArticleId><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Blann A.D., Heitmar R. SARS-CoV-2 and COVID-19: A Narrative Review. Br. J. Biomed. Sci. 2022;79:10426. doi: 10.3389/bjbs.2022.10426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/bjbs.2022.10426</ArticleId><ArticleId IdType="pmc">PMC9486701</ArticleId><ArticleId IdType="pubmed">36148046</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratton C.W., Tang Y.W., Lu H. Pathogenesis-directed therapy of 2019 novel coronavirus disease. J. Med. Virol. 2021;93:1320&#x2013;1342. doi: 10.1002/jmv.26610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26610</ArticleId><ArticleId IdType="pubmed">33073355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch C., Park Y.S., Piechotta V., Chai K.L., Estcourt L.J., Monsef I., Salomon S., Wood E.M., So-Osman C., McQuilten Z., et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst. Rev. 2022;6:CD014945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9205158</ArticleId><ArticleId IdType="pubmed">35713300</ArticleId></ArticleIdList></Reference><Reference><Citation>Saravolatz L.D., Depcinski S., Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs. Clin. Infect. Dis. 2022:ciac180. doi: 10.1093/cid/ciac180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac180</ArticleId><ArticleId IdType="pmc">PMC9383515</ArticleId><ArticleId IdType="pubmed">35245942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan M., Nirula A., Azizad M., Mocherla B., Gottlieb R.L., Chen P., Hebert C., Perry R., Boscia J., Heller B., et al. BLAZE-1 Investigators. Bamlanivimab plus Etesevimab in Mild or Moderate COVID-19. N. Engl. J. Med. 2021;385:1382&#x2013;1392. doi: 10.1056/NEJMoa2102685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102685</ArticleId><ArticleId IdType="pmc">PMC8314785</ArticleId><ArticleId IdType="pubmed">34260849</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich D.M., Sivapalasingam S., Norton T., Ali S., Gao H., Bhore R., Xiao J., Hooper A.T., Hamilton J.D., Musser B.J., et al. Trial Investigators. REGEN-COV Antibody Combination and Outcomes in Outpatients with COVID-19. N. Engl. J. Med. 2021;385:e81. doi: 10.1056/NEJMoa2108163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108163</ArticleId><ArticleId IdType="pmc">PMC8522800</ArticleId><ArticleId IdType="pubmed">34587383</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Gonzalez-Rojas Y., Juarez E., Crespo Casal M., Moya J., Falci D.R., Sarkis E., Solis J., Zheng H., Scott N., et al. COMET-ICE Investigators. Early Treatment for COVID-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N. Engl. J. Med. 2021;385:1941&#x2013;1950. doi: 10.1056/NEJMoa2107934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107934</ArticleId><ArticleId IdType="pubmed">34706189</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Mart&#xed;n-Quir&#xf3;s A., Caraco Y., Williams-Diaz A., Brown M.L., et al. MOVe-OUT Study Group. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N. Engl. J. Med. 2022;386:509&#x2013;520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Sim&#xf3;n-Campos A., et al. EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N. Engl. J. Med. 2022;386:1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O&#x2019;Hara M., Suett J., Dahmash D., Bugaeva P., et al. Characterising long COVID: A living systematic review. BMJ Glob. Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer R.R., Rock M.A., Vasilevsky N., Carmody L., Rando H., Anzalone A.J., Basson M.D., Bennett T.D., Bergquist T., Boudreau E.A., et al. Characterizing Long COVID: Deep Phenotype of a Complex Condition. EBioMedicine. 2021;74:103722. doi: 10.1016/j.ebiom.2021.103722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103722</ArticleId><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mnatzaganian G., Davidson D.C., Hiller J.E., Ryan P. Propensity score matching and randomization. J. Clin. Epidemiol. 2015;68:760&#x2013;768. doi: 10.1016/j.jclinepi.2015.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.01.002</ArticleId><ArticleId IdType="pubmed">25660052</ArticleId></ArticleIdList></Reference><Reference><Citation>Daitch V., Yelin D., Awwad M., Guaraldi G., Mili&#x107; J., Mussini C., Falcone M., Tiseo G., Carrozzi L., Pistelli F., et al. ESCMID study group for infections in the elderly (ESGIE). Characteristics of long COVID among older adults: A cross-sectional study. Int. J. Infect. Dis. 2022. in press .</Citation><ArticleIdList><ArticleId IdType="pubmed">36191820</ArticleId></ArticleIdList></Reference><Reference><Citation>Floridia M., Grassi T., Giuliano M., Tiple D., Pricci F., Villa M., Silenzi A., Onder G. Characteristics of Long-COVID care centers in Italy. A national survey of 124 clinical sites. Front. Public Health. 2022;10:975527. doi: 10.3389/fpubh.2022.975527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.975527</ArticleId><ArticleId IdType="pmc">PMC9437305</ArticleId><ArticleId IdType="pubmed">36062113</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinicci M., Vellere I., Graziani L., Tilli M., Borchi B., Mencarini J., Campolmi I., Gori L., Rasero L., Fattirolli F., et al. Careggi Post-acute COVID-19 Study Group. Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center. Open Forum Infect. Dis. 2021;8:ofab049. doi: 10.1093/ofid/ofab049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab049</ArticleId><ArticleId IdType="pmc">PMC7928559</ArticleId><ArticleId IdType="pubmed">34109256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko J.Y., Danielson M.L., Town M., Derado G., Greenlund K.J., Kirley P.D., Alden N.B., Yousey-Hindes K., Anderson E.J., Ryan P.A., et al. COVID-NET Surveillance Team. Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin. Infect. Dis. 2021;72:e695&#x2013;e703. doi: 10.1093/cid/ciaa1419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1419</ArticleId><ArticleId IdType="pmc">PMC7543371</ArticleId><ArticleId IdType="pubmed">32945846</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng D.O., Hurst J.R. COVID-19 and &#x2018;basal&#x2019; exacerbation frequency in COPD. Thorax. 2021;76:432&#x2013;433. doi: 10.1136/thoraxjnl-2020-216637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216637</ArticleId><ArticleId IdType="pubmed">33443208</ArticleId></ArticleIdList></Reference><Reference><Citation>Salciccioli J.D., She L., Tulchinsky A., Rockhold F., Cardet J.C., Israel E. Effect of COVID-19 on asthma exacerbation. J. Allergy Clin. Immunol. Pract. 2021;9:2896&#x2013;2899.e1. doi: 10.1016/j.jaip.2021.04.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2021.04.038</ArticleId><ArticleId IdType="pmc">PMC8086260</ArticleId><ArticleId IdType="pubmed">33940216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollborn J., Karamnov S., Fields K.G., Yeh T., Muehlschlegel J.D. COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients. Sci. Rep. 2022;12:12014. doi: 10.1038/s41598-022-16113-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-16113-6</ArticleId><ArticleId IdType="pmc">PMC9281233</ArticleId><ArticleId IdType="pubmed">35835807</ArticleId></ArticleIdList></Reference><Reference><Citation>Ates O., Yilmaz I., Karaarslan N., Ersoz E., Hacioglu Kasim F.B., Dogan M., Ozbek H. Coexistence of SARS-CoV-2 and cerebrovascular diseases: Does COVID-19 positivity trigger cerebrovascular pathologies? J. Infect. Dev. Ctries. 2022;16:981&#x2013;992. doi: 10.3855/jidc.15800.</Citation><ArticleIdList><ArticleId IdType="doi">10.3855/jidc.15800</ArticleId><ArticleId IdType="pubmed">35797292</ArticleId></ArticleIdList></Reference><Reference><Citation>Taxonera C., Fisac J., Alba C. Can COVID-19 Trigger De Novo Inflammatory Bowel Disease? Gastroenterology. 2021;160:1029&#x2013;1030. doi: 10.1053/j.gastro.2020.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.11.026</ArticleId><ArticleId IdType="pmc">PMC7676850</ArticleId><ArticleId IdType="pubmed">33221408</ArticleId></ArticleIdList></Reference><Reference><Citation>Korompoki E., Gavriatopoulou M., Fotiou D., Ntanasis-Stathopoulos I., Dimopoulos M.A., Terpos E. Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. Am. J. Hematol. 2022;97:119&#x2013;128. doi: 10.1002/ajh.26384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26384</ArticleId><ArticleId IdType="pmc">PMC8646944</ArticleId><ArticleId IdType="pubmed">34687462</ArticleId></ArticleIdList></Reference><Reference><Citation>Aram K., Patil A., Goldust M., Rajabi F. COVID-19 and exacerbation of dermatological diseases: A review of the available literature. Dermatol. Ther. 2021;34:e15113. doi: 10.1111/dth.15113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.15113</ArticleId><ArticleId IdType="pmc">PMC8646294</ArticleId><ArticleId IdType="pubmed">34453380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf S., Imran M.A., Ashraf S., Hafsa H.T., Khalid S., Akram M.K., Ghufran M., Cheema K.K., Ahmad A., Izhar M. COVID-19: A Potential Trigger for Thyroid Dysfunction. Am. J. Med. Sci. 2021;362:303&#x2013;307. doi: 10.1016/j.amjms.2021.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2021.05.013</ArticleId><ArticleId IdType="pmc">PMC8137358</ArticleId><ArticleId IdType="pubmed">34023311</ArticleId></ArticleIdList></Reference><Reference><Citation>Buicu A.L., Cernea S., Benedek I., Buicu C.F., Benedek T. Systemic Inflammation and COVID-19 Mortality in Patients with Major Noncommunicable Diseases: Chronic Coronary Syndromes, Diabetes and Obesity. Clin. Med. 2021;10:1545. doi: 10.3390/jcm10081545.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10081545</ArticleId><ArticleId IdType="pmc">PMC8067631</ArticleId><ArticleId IdType="pubmed">33916917</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu S.X., Tyagi T., Jain K., Gu V.W., Lee S.H., Hwa J.M., Kwan J.M., Krause D.S., Lee A.I., Halene S., et al. Thrombocytopathy and endotheliopathy: Crucial contributors to COVID-19 thromboinflammation. Nat. Rev. Cardiol. 2021;18:194&#x2013;209. doi: 10.1038/s41569-020-00469-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-00469-1</ArticleId><ArticleId IdType="pmc">PMC7675396</ArticleId><ArticleId IdType="pubmed">33214651</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., Peligro P.J., Casimiro M., Guerrero J.J., Gellaco M.M.L., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>